دورية أكاديمية
أعرض في EDS

The evaluation of in vitro antichagasic and anti -SARS-CoV-2 potential of inclusion complexes of β- and methyl-β-cyclodextrin with naphthoquinone.

التفاصيل البيبلوغرافية
العنوان: The evaluation of in vitro antichagasic and anti -SARS-CoV-2 potential of inclusion complexes of β- and methyl-β-cyclodextrin with naphthoquinone.
المؤلفون: Oliveira VDS; Department of Pharmacy, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, 59012-570, Brazil., Silva CC; School of Technology, State University of Amazonas, Manaus, Amazonas, 69065-020, Brazil., de Freitas Oliveira JW; Department of Pharmacy, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, 59012-570, Brazil., da Silva MS; Department of Pharmacy, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, 59012-570, Brazil.; Global Health and Tropical Medicine, Institute of Hygiene and Tropical Medicine, NOVA University Lisbon, Lisbon, 1800-166, Portugal., Ferreira PG; Department of Pharmaceutical Technology, Faculty of Pharmacy, Fluminense Federal University, Niterói, Rio de Janeiro, 24241-002, Brazil., da Siva FC; Institute of Chemistry, Fluminense Federal University, Niterói, Rio de Janeiro, 24020-150, Brazil., Ferreira VF; Department of Pharmaceutical Technology, Faculty of Pharmacy, Fluminense Federal University, Niterói, Rio de Janeiro, 24241-002, Brazil., Barbosa EG; Department of Pharmacy, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, 59012-570, Brazil., Barbosa CG; Department of Microbiology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, São Paulo, 05508-900, Brazil., Moraes CB; Department of Microbiology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, São Paulo, 05508-900, Brazil.; Department of Pharmaceutical Sciences, Federal University of São Paulo, São Paulo, São Paulo, 09913-030, Brazil., Freitas-Junior LHG; Department of Microbiology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, São Paulo, 05508-900, Brazil., Converti A; Department of Civil, Chemical and Environmental Engineering, University of Genoa, Pole of Chemical Engineering, via Opera Pia 15, 16145, Genoa, Italy., Lima ÁAN; Department of Pharmacy, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, 59012-570, Brazil.
المصدر: Journal of drug delivery science and technology [J Drug Deliv Sci Technol] 2023 Mar; Vol. 81, pp. 104229. Date of Electronic Publication: 2023 Feb 08.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: France NLM ID: 101214432 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1773-2247 (Print) Linking ISSN: 17732247 NLM ISO Abbreviation: J Drug Deliv Sci Technol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: <2015- > : Paris Elsevier
Original Publication: Paris [France] : Ed. de santé, c2004-
مستخلص: The compound 3 a ,10 b -dihydro-1 H -cyclopenta[ b ]naphtho[2,3- d ]furan-5,10-dione (IVS320) is a naphthoquinone with antifungal and antichagasic potential, which however has low aqueous solubility. To increase bioavailability, inclusion complexes with β-cyclodextrin (βCD) and methyl-β-cyclodextrin (MβCD) were prepared by physical mixture (PM), kneading (KN) and rotary evaporation (RE), and their in vitro anti -SARS-CoV-2 and antichagasic potential was assessed. The formation of inclusion complexes led to a change in the physicochemical characteristics compared to IVS320 alone as well as a decrease in crystallinity degree that reached 74.44% for the IVS320-MβCD one prepared by RE. The IVS320 and IVS320-MβCD/RE system exhibited anti -SARS-CoV-2 activity, showing half maximal effective concentrations (EC 50 ) of 0.47 and 1.22 μg/mL, respectively. Molecular docking simulation suggested IVS320 ability to interact with the SARS-CoV-2 viral protein. Finally, the highest antichagasic activity, expressed as percentage of Tripanosoma cruzi growth inhibition, was observed with IVS320-βCD/KN (70%) and IVS320-MβCD/PM (72%), while IVS320 alone exhibited only approximately 48% inhibition at the highest concentration (100 μg/mL).
Competing Interests: The authors declare no competing interest.
(© 2023 Elsevier B.V. All rights reserved.)
References: Eur J Med Chem. 2013 Feb;60:51-6. (PMID: 23279867)
J Comput Chem. 2004 Oct;25(13):1605-12. (PMID: 15264254)
Planta Med. 2017 May;83(7):631-635. (PMID: 27852095)
Carbohydr Polym. 2015 Oct 20;131:297-305. (PMID: 26256188)
Saudi Pharm J. 2020 Jan;28(1):136-146. (PMID: 31920439)
Biomed Pharmacother. 2019 Jan;109:779-787. (PMID: 30551531)
Chem Pharm Bull (Tokyo). 2020;68(1):46-57. (PMID: 31902901)
Int J Pharm. 2018 Jan 15;535(1-2):272-284. (PMID: 29138045)
Pharmaceutics. 2020 Nov 24;12(12):. (PMID: 33255502)
J Cheminform. 2012 Aug 13;4(1):17. (PMID: 22889332)
J Mol Model. 2013 Jan;19(1):1-32. (PMID: 23187683)
J Nat Prod. 1996 Aug;59(8):808-11. (PMID: 8792629)
Org Biomol Chem. 2015 Jan 14;13(2):428-37. (PMID: 25370790)
Molecules. 2017 Sep 30;22(10):. (PMID: 28973960)
J Biomol Struct Dyn. 2021 Sep;39(15):5735-5755. (PMID: 32679006)
Int J Pharm. 2015 Oct 15;494(1):408-16. (PMID: 26315120)
J Pharm Biomed Anal. 2005 Sep 15;39(3-4):824-9. (PMID: 16011886)
Molecules. 2019 Apr 02;24(7):. (PMID: 30986933)
Mater Sci Eng C Mater Biol Appl. 2020 Jan;106:110161. (PMID: 31753384)
ACS Omega. 2017 Dec 31;2(12):9080-9094. (PMID: 30023600)
J Pharm Sci. 2011 Jun;100(6):2443-51. (PMID: 21491453)
Int J Mol Sci. 2020 Jan 31;21(3):. (PMID: 32023867)
Acta Pharmacol Sin. 2020 Sep;41(9):1167-1177. (PMID: 32737471)
Beilstein J Org Chem. 2014 Dec 16;10:2997-3006. (PMID: 25670970)
Anticancer Agents Med Chem. 2013 Dec;13(10):1500-7. (PMID: 23848207)
Biomolecules. 2019 Sep 27;9(10):. (PMID: 31569832)
J Comput Chem. 2010 Jan 30;31(2):455-61. (PMID: 19499576)
Molecules. 2018 Nov 29;23(12):. (PMID: 30501061)
Molecules. 2021 Aug 12;26(16):. (PMID: 34443484)
Mem Inst Oswaldo Cruz. 2020 Feb 14;115:e190389. (PMID: 32074167)
Exp Eye Res. 2019 Dec;189:107829. (PMID: 31605685)
Pharmaceutics. 2020 Sep 30;12(10):. (PMID: 33007806)
Sci Rep. 2021 Nov 17;11(1):22440. (PMID: 34789826)
Molecules. 2015 Jun 30;20(7):11994-2015. (PMID: 26133763)
Exp Parasitol. 2011 Jan;127(1):160-6. (PMID: 20647011)
J Med Chem. 2016 Jul 28;59(14):6595-628. (PMID: 26878082)
فهرسة مساهمة: Keywords: Anti-SARS-CoV-2; Antichagasic activity; Inclusion complexes; Naphthoquinone
تواريخ الأحداث: Date Created: 20230213 Latest Revision: 20231106
رمز التحديث: 20231106
مُعرف محوري في PubMed: PMC9905044
DOI: 10.1016/j.jddst.2023.104229
PMID: 36776572
قاعدة البيانات: MEDLINE
الوصف
تدمد:1773-2247
DOI:10.1016/j.jddst.2023.104229